In the JDRF-funded Medalist Study of individuals who have lived with T1D for at least 50 years, researchers have discovered that some Medalists are protected from advanced diabetic retinopathy because they have a slow rate of retinopathy onset or progression. Further, after 20 years of T1D, progression of retinopathy appears to halt. Researchers can now search for factors that mediate this slow disease progression and exploit them to develop new strategies to prevent or treat diabetic retinopathy.
In one of the largest studies of its kind, JDRF has partnered with iCo Therapeutics to investigate a potential new drug that could, if successful, broaden treatment options for people living with DME. The Phase II trial, led and coordinated by Johns Hopkins University investigators, is currently recruiting participants. To inquire about participation, please contact Dr. Quan Dong Nguyen or click here.